
XRAY
DENTSPLY SIRONA Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
16.290
Open
16.060
VWAP
--
Vol
2.17M
Mkt Cap
3.21B
Low
15.990
Amount
--
EV/EBITDA(TTM)
8.56
Total Shares
207.63M
EV
5.07B
EV/OCF(TTM)
11.46
P/S(TTM)
0.87
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. It develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices. Its Connected Technology Solutions segment includes design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of its value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and dental professional-directed aligner solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for urinary and bowel management.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
932.93M
-5.19%
0.497
+1.53%
899.68M
-5.4%
0.458
-8.37%
939.84M
+3.85%
0.496
+90.87%
Estimates Revision
The market is revising Upward the revenue expectations for DENTSPLY SIRONA Inc. (XRAY) for FY2025, with the revenue forecasts being adjusted by 2.02% over the past three months. During the same period, the stock price has changed by 15.90%.
Revenue Estimates for FY2025
Revise Upward

+2.02%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+3.34%
In Past 3 Month
Stock Price
Go Up

+15.90%
In Past 3 Month
12 Analyst Rating

10.49% Upside
Wall Street analysts forecast XRAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XRAY is 17.80 USD with a low forecast of 14.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
9 Hold
0 Sell
Hold

10.49% Upside
Current: 16.110

Low
14.00
Averages
17.80
High
25.00

10.49% Upside
Current: 16.110

Low
14.00
Averages
17.80
High
25.00
Leerink
Market Perform
maintain
$17
2025-07-14
Reason
Leerink
Price Target
$17
2025-07-14
maintain
Market Perform
Reason
Leerink raised the firm's price target on Dentsply Sirona to $17 from $16.50 and keeps a Market Perform rating on the shares. Heading into Q2 earnings, the firm is updating dental company estimates and publishing the results of its fourth semi-annual dental survey of 63 dental practitioners in the United States. There is clearly a budding interest in identifying incremental improvements across the dental space, even if each opportunity seems to be company-specific in what remains a still-challenged total dental end-market, Leerink says. The firm sees reasons to be positive on each stock in its coverage but also has some offsetting questions that limit too much constructiveness.
Barrington
Michael Petusky
Outperform
maintain
$20 -> $21
2025-05-12
Reason
Barrington
Michael Petusky
Price Target
$20 -> $21
2025-05-12
maintain
Outperform
Reason
Barrington analyst Michael Petusky raised the firm's price target on Dentsply Sirona to $21 from $20 and keeps an Outperform rating on the shares. While stating that "one quarter of beating very muted expectations does not a turnaround make," the firm believes this quarter may suggest the start of a stabilization of this business and although it remains cautious, it believes that "at this valuation level, the risk/reward continues to favor investment."
UBS
Buy
downgrade
$27 -> $25
2025-05-09
Reason
UBS
Price Target
$27 -> $25
2025-05-09
downgrade
Buy
Reason
UBS lowered the firm's price target on Dentsply Sirona to $25 from $27 and keeps a Buy rating on the shares.
Evercore ISI
In Line
maintain
$15 -> $17
2025-05-08
Reason
Evercore ISI
Price Target
$15 -> $17
2025-05-08
maintain
In Line
Reason
Evercore ISI raised the firm's price target on Dentsply Sirona to $17 from $15 and keeps an In Line rating on the shares. The firm notes that the company's Q1 earnings provide further data points that dental is starting to recover post its COVID hangover. While not out of the woods yet, and clearly tariffs and macro concerns are weighing on results, better ex-U.S. sentiment should also help to offset a portion of the macro pressure, Evercore argues. Dentsply still has "a lot of wood to chop" to get the dental business on the right long-term track, but the firm is encouraged by the hard work that is being done to get there. However, it remains on the sidelines until it sees signs that these operational improvements are starting to yield greater financial results.
Mizuho
Neutral
downgrade
$18 -> $16
2025-04-24
Reason
Mizuho
Price Target
$18 -> $16
2025-04-24
downgrade
Neutral
Reason
Mizuho lowered the firm's price target on Dentsply Sirona to $16 from $18 and keeps a Neutral rating on the shares. The firm believes many companies in the dental sector "may post less-than-stellar growth" in Q1. The recent American Dental Association Q1 survey results further reinforce a cautious view, so Mizuho trimmed Q1 estimates for broad dental manufacturers, the analyst tells investors in a research note.
Needham
David Saxon
Strong Buy
to
Hold
Downgrades
n/a
2025-03-13
Reason
Needham
David Saxon
Price Target
n/a
2025-03-13
Downgrades
Strong Buy
to
Hold
Reason
Needham analyst David Saxon downgraded Dentsply Sirona to Hold from Buy without a price target. With a debate around whether the dental market's long-term growth profile has shifted lower and recent indicators pointing to weakening U.S. consumer sentiment, Needham does not expect dental market growth to improve in the near-term, the analyst tells investors in a research note. The firm says that with Dentsply and ZimVie both seeing below-market growth and no meaningful upside catalyst to drive near-term multiple expansion, it no longer believes the stocks can outperform relative to its broader coverage.
See All Ratings
Valuation Metrics
The current forward P/E ratio for DENTSPLY SIRONA Inc (XRAY.O) is 8.35, compared to its 5-year average forward P/E of 17.11. For a more detailed relative valuation and DCF analysis to assess DENTSPLY SIRONA Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued
5Y Average PE
17.11
Current PE
8.35
Overvalued PE
21.89
Undervalued PE
12.33
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued
5Y Average EV/EBITDA
12.51
Current EV/EBITDA
7.37
Overvalued EV/EBITDA
15.22
Undervalued EV/EBITDA
9.81
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
2.07
Current PS
0.87
Overvalued PS
2.81
Undervalued PS
1.32
Financials
Annual
Quarterly
FY2025Q1
YoY :
-7.76%
879.00M
Total Revenue
FY2025Q1
YoY :
+40.38%
73.00M
Operating Profit
FY2025Q1
YoY :
+11.76%
19.00M
Net Income after Tax
FY2025Q1
YoY :
+11.11%
0.10
EPS - Diluted
FY2025Q1
YoY :
+33.33%
-12.00M
Free Cash Flow
FY2025Q1
YoY :
-0.17%
53.01
Gross Profit Margin - %
FY2025Q1
YoY :
+5.65%
7.48
FCF Margin - %
FY2025Q1
YoY :
+21.35%
2.16
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
250.0K
USD
Months
6-9
1
200.3K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
4.6M
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
855.3K
Volume
Months
6-9
3
3.0M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
32.0K
USD
4
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
250.0K
USD
Months
6-9
1
200.3K
USD
Months
0-12
0
0.0
USD
Months
XRAY News & Events
Events Timeline
2025-07-21 (ET)
2025-07-21
11:42:53
Roth bullish on Globus Medical amid CEO Transition, solid pre-reported results

2025-07-21
08:38:38
Dentsply Sirona appoints Scavilla as Chief Executive Officer

2025-05-08 (ET)
2025-05-08
06:08:30
Dentsply Sirona backs FY25 adjusted EPS view $1.80-$2.00, consensus $1.80

Sign Up For More Events
Sign Up For More Events
News
3.0
07-25NASDAQ.COMPeek Under The Hood: ONEV Has 10% Upside
5.0
07-21NASDAQ.COMDentsply Sirona CEO Simon Campion To Quit, Daniel Scavilla To Succeed; Announces Q2 Prelim. Results
5.0
07-21NewsfilterDentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer
Sign Up For More News
People Also Watch

RARE
Ultragenyx Pharmaceutical Inc
27.660
USD
+0.18%

SKT
Tanger Inc
31.060
USD
+0.19%

BL
BlackLine Inc
55.750
USD
+0.09%

ALIT
Alight Inc
5.540
USD
-2.64%

HAE
Haemonetics Corp
75.540
USD
+1.18%

SHC
Sotera Health Co
12.140
USD
-1.22%

ATGE
Adtalem Global Education Inc
113.940
USD
+0.10%

DXC
DXC Technology Co
14.130
USD
-0.70%

LBRT
Liberty Energy Inc
12.820
USD
-1.84%

APLS
Apellis Pharmaceuticals Inc
18.950
USD
+1.07%
FAQ

What is DENTSPLY SIRONA Inc (XRAY) stock price today?
The current price of XRAY is 16.11 USD — it has increased 0.25 % in the last trading day.

What is DENTSPLY SIRONA Inc (XRAY)'s business?

What is the price predicton of XRAY Stock?

What is DENTSPLY SIRONA Inc (XRAY)'s revenue for the last quarter?

What is DENTSPLY SIRONA Inc (XRAY)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for DENTSPLY SIRONA Inc (XRAY)'s fundamentals?

How many employees does DENTSPLY SIRONA Inc (XRAY). have?
